Results 81 to 90 of about 411,617 (199)

Basal insulin degludec - liraglutide fixed ratio combination (Xultophy(R))

, 2018
peer reviewedXultophy(R) (IDegLira) is a fixed ratio combination of basal insulin degludec and glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide.
Scheen, André, Mathieu, Chantal
core   +1 more source

Cost-effectiveness of insulin degludec versus insulin glargine U100 in patients with type 1 and type 2 diabetes in Portugal: evidence from SWITCH 1&2 trials [PDF]

, 2020
Objectives: To assess the cost-effectiveness of insulin degludec (degludec) versus insulin glargine (glargine) U100 from a Portuguese healthcare perspective using data from SWITCH 1 & 2 trials.
Carvalho, Davide, Conde, Vasco, Ascanio, Meritxell, Darbà, Josep, Pedersen, Kasper S.   +4 more
core   +1 more source

Pediatric diabetes: Potential for insulin degludec

Indian Journal of Endocrinology and Metabolism, 2014
Comprehensive guidelines, published recently by the International Society for Pediatric and Adolescent Diabetes (ISPAD) describe the use of insulin in children and adolescents in great detail.[1] These guidelines provide a bird's eye view of the subject, and also clarify micro management issues, which challenge the pediatric diabetes care provider from
Sanjay Kalra, Ambika Gopalakrishnan Unnikrishnan, Rakesh Sahay   +2 more
openaire   +3 more sources

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.

, 2012
International audienceBACKGROUND: Intensive basal-bolus insulin therapy has been shown to improve glycaemic control and reduce the risk of long-term complications that are associated with type 1 diabetes mellitus.
Bode, Bruce, Fisher, Miles, Russell-Jones, David, Pei, Huiling, Heller, Simon, Buse, John, Kerlan, Véronique, Francisco, Ann Marie Ocampo, Garg, Satish, Merker, Ludwig, Philotheou, Areti, Marre, Michel, Renard, Eric   +12 more
core   +1 more source

A cost-utility analysis of long-acting insulin analogues (detemir, glargine and degludec) for the treatment of adult type 1 diabetes in South Africa

Cost Effectiveness and Resource Allocation
Background Type 1 Diabetes Mellitus (T1DM) is a life-threatening condition that is managed with administered insulin. Intermediate- to long-acting insulin represents the basal insulin constituent of the total insulin used in treating T1DM.
Mark T. Verryn, Susan Cleary
doaj   +1 more source

Once-Weekly Subcutaneous Insulin Efsitora for the Management of Diabetes Mellitus: A Systematic Review and Meta-Analysis Study

Medeniyet Medical Journal
Even though insulin therapy is the cornerstone of diabetes mellitus management, multiple daily injections are associated with poor adherence. Once-weekly basal insulin therapy has emerged as a novel therapeutic approach and is being evaluated in multiple
Sidar COPUR, Berk MIZRAK, Lasin OZBEK, Duygu UCKU, Adnan BATMAN, Abduzhappar GAIPOV, Adrian COVIC, Daniel van RAALTE, Mehmet KANBAY   +8 more
doaj   +1 more source

Efficacy and safety of basal insulins in people with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials

Frontiers in Endocrinology
AimThe comparative effectiveness of basal insulins has been examined in several studies. However, current treatment algorithms provide a list of options with no clear differentiation between different basal insulins as the optimal choice for initiation ...
Mohsen Dehghani, Masoumeh Sadeghi, Masoumeh Sadeghi, Farzaneh Barzkar, Zohreh Maghsoomi, Leila Janani, Seyed Abbas Motevalian, Yoon K. Loke, Faramarz Ismail-Beigi, Hamid Reza Baradaran, Hamid Reza Baradaran, Hamid Reza Baradaran, Mohammad E. Khamseh   +12 more
doaj   +1 more source

Comparative efficacy and safety of three fixed‐ratio combination products in type 2 diabetes: A network meta‐analysis

Journal of Diabetes Investigation
Objective To systematically evaluate and compare the efficacy and safety of three fixed‐ratio combination products—insulin degludec/liraglutide (IDegLira), insulin glargine/lixisenatide (iGlarLixi), and insulin degludec/insulin aspart (IDegAsp)—in ...
Xiaomei Wang, Jiali Qin, Yang Liu, Xianying Wang   +3 more
doaj   +1 more source

[Basal insulin degludec - liraglutide fixed ratio combination (Xultophy®)].

, 2018
Xultophy® (IDegLira) is a fixed ratio combination of basal insulin degludec and glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide. Insulin degludec is characterized by an original mode of prolonged and continuous insulin diffusion after its ...
Scheen, A.J., Mathieu, C.
core  

Degludek: napjaink ideális bázisinzulinja? [Degludec: the ideal basal insulin of today]

, 2019
A degludek egy ultrahosszú hatású bázis-inzulinanalóg, amelyből a B30-as pozíciójú treonint eltávolították és a B29-es lizinhez egy 16 szénatomos zsírsavat kapcsoltak. Az injekció beadása után a degludek a subcutan térben oldékony multihexamereket képez.
Gerő, László
core   +1 more source